Efavirenz concentrations in HIV-infected patients with and without viral hepatitis

British Journal of Clinical Pharmacology

Volumn 66, Issue 4, 2008, Pages 551-555

  Pereira, Sofia A ^a   Caixas, Umbelina ^a,c   Branco, Teresa ^b,c   Germano, Isabel ^c   Lampreia, Fátima ^c   Papoila, Ana L ^a   Monteiro, Emília C ^a  

^a UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^b HOSPITAL FERNANDO FONSECA   (Portugal)

^c Centro Hospitalar de Lisboa Central   (Portugal)

Author keywords

Efavirenz concentrations; Liver function; Viral hepatitis co infection

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; EFAVIRENZ; GAMMA GLUTAMYLTRANSFERASE; LAMIVUDINE; PEGINTERFERON; RIBAVIRIN; ZIDOVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FUNCTION; LIVER TOXICITY; MALE; MIXED INFECTION; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; BENZOXAZINES; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER DISEASES; MALE; PILOT PROJECTS; REVERSE TRANSCRIPTASE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VIRAL LOAD;

EID: 51649096977     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03238.x     Document Type: Article

References (30)

1. Lok AS, McMahon BJ. Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology 2004 39: 857 61.
2. Dodig M, Tavill AS. Hepatitis C and human immunodeficiency virus coinfections. J Clin Gastroenterol 2001 33: 367 74.
3. Staples CT, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis 1999 29: 150 4.
4. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, Snydman DR. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001 32: 492 7.
5. Mutlib AE, Chen H, Nemeth G, Gan LS, Christ DD. Liquid chromatography/mass spectrometry and high-field nuclear magnetic resonance characterization of novel mixed diconjugates of the non-nucleoside human immunodeficiency virus-1 reverse transcriptase inhibitor, efavirenz. Drug Metab Dispos 1999 27: 1045 56.
6. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001 15: 71 5.
7. Nunez M, Gonzalez de Requena D, Gallego L, Jiminez-Nacher I, Gonzalez-Lahoz J, Soriano V. Higher efavirenz plasma levels correlate with development of insomnia. J Acquir Immune Defic Syndr 2001 28: 399 400.
8. Gutierrez F, Navarro A, Padilla S, Anton R, Masiá M, Borrás J, Martín-Hidalgo A. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis 2005 41: 1648 53.
9. Rivero A, Mira JA, Pineda JA. Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother 2007 59: 342 6.
10. Bossi P, Colin D, Bricaire F, Caumes E. Hypersensitivity syndrome associated with efavirenz therapy. Clin Infect Dis 2000 30: 227 8.
11. Angel-Moreno-Maroto A, Suarez-Castellano L, Hernandez-Cabrera M, Perez-Arellano JL. Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure. J Infect 2006 52: 39 40.
12. Kappelhoff BS, van Leth F, Robinson PA, MacGregor TR, Baraldi E, Montella F, Uip DE, Thompson MA, Russell DB, Lange JM, Beijnen JH, Huitema AD 2NN Study Group. Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir Ther 2005 10: 489 98.
13. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002 35: 182 9.
14. Martin-Carbonero L, Nunez M, Gonzalez-Lahoz J, Soriano V. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clin Trials 2003 4: 115 20.
15. Ena J, Amador C, Benito C, Fenoll V, Pasquau F. Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients. Int J STD AIDS 2003 14: 776 81.
16. Rodriguez-Novoa S, Barreiro P, Rendon A, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V. Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis 2005 40: 1358 61.
17. Gibbons S, Taylor C, Waldron S, Back DJ, Weber J, Khoo SH. Therapeutic drug monitoring of NNRTIs in patients with hepatic dysfunction. 6th International Congress on Drug Therapy in HIV Infection, Glasgow, 2002 Abstract P174.
18. Maserati R, Villani P, Seminari E, Pan A, Lo Caputo S, Regazzi MB. High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease. AIDS 1999 13: 870 1.
19. Bickel M, Stephan C, Rottmann C, Carlebach A, Haberl A, Kurowski M, Staszewski S. Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis. Scand J Infect Dis 2005 37: 520 2.
20. Robertson SM, Scarsi KK, Postelnick MJ, Lynch P. Elevated plasma concentrations of protease inhibitors and nonnucleoside reverse transcriptase inhibitors in patients coinfected with human immunodeficiency virus and hepatitis B or C: case series and literature review. Pharmacotherapy 2005 25: 1068 72.
21. Barreiro P, Rodriguez-Novoa S, Labarga P, Ruiz A, Jiménez- Nácher I, Martín-Carbonero L, Gonzalez-Lahoz J, Soriano V. Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. J Infect Dis 2007 195: 973 9.
22. Pereira SA, Branco T, Caixas U, Côrte-Real RM, Germano I, Lampreia F, Monteiro EC. Intra-individual variability in efavirenz plasma concentrations supports therapeutic drug monitoring based on quarterly sampling in the first year of Therapy. Ther Drug Monit 2008 30: 60 6.
23. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ 2005 172: 367 79.
24. Giannini E, Risso D, Botta F, Chiarbonello B, Fasoli A, Malfatti F, Romagnoli P, Testa E, Ceppa P, Testa R. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003 163: 218 24.
25. Geffriaud C, Poynard T, Delfraissy JF, Bedossa P, Naveau S, Bourée P, Dubreuil P, Chaput JC. Hepatic involvement in HIV 1 virus infection. Gastroenterol Clin Biol 1988 12: 465 72.
26. Fonquernie L, Serfaty L, Charrois A, Wendum D, Lefebvre B, Girard PM, Meynard JL. Significance of hepatitis C virus coinfection with persistently normal alanine aminotransferase levels in HIV-1-infected patients. HIV Med 2004 5: 385 90.
27. Butt AA, Tsevat J, Ahmad J, Shakil AO, Mrus JM. Biochemical and virologic parameters in patients co-infected with hepatitis C and HIV versus patients with hepatitis C mono-infection. Am J Med Sci 2007 333: 271 5.
28. Renton KW. Cytochrome P450 regulation and drug biotransformation during inflammation and infection. Curr Drug Metab 2004 5: 235 43.
29. Csajka C, Marzolini C, Fattinger K, Decosterd LA, Fellay J, Telenti A, Biollaz J, Buclin T. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther 2003 73: 20 30.
30. Stahle L, Moberg L, Svensson JO, Sonnerborg A. Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects. Ther Drug Monit 2004 26: 267 70.